FDA Approves First Generic Version of Rifapentine for Tuberculosis Treatment

The U.S. Food and Drug Administration (FDA) has approved the first generic version of rifapentine (Priftin, Sanofi-Aventis) tablets. This approval covers the treatment of active pulmonary tuberculosis disease and latent TB infection, offering a new, more accessible option for patients.